Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 206

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A Randomized, Placebo-Controlled Trial Assessing the Effects of Rosiglitazone on Echocardiographic Function and Cardiac Status in Type 2 Diabetic Patients With New York Heart Association Functional Class I or II Heart Failure

Open access
Dargie, Henry J., Hildebrandt, Per R., Riegger, Günter A.J., McMurray, John J.V., McMorn, Stephen O., Roberts, Jeremy N., Zambanini, Andrew, Wilding, John P.H. · 2007 · Journal of the American College of Cardiology

Abstract

OBJECTIVES This study investigated the effects of rosiglitazone (RSG) on left ventricular ejection fraction (LVEF) in subjects with type 2 diabetes (T2DM) and pre-existing chronic heart failure (CHF) (New York Heart Association [NYHA] functional class I to II). BACKGROUND Fluid retention is an important consideration in the use of thiazolidinediones in T2DM patients because it could exacerbate symptoms or precipitate decompensation in those with previously stable CHF. METHODS A total of 224 patients with T2DM and NYHA functional class I to II CHF with LVEF < or =45% were randomized to a 52-week treatment with RSG (4 to 8 mg daily, n = 110) or placebo (PLB) (n = 114) in addition to background antidiabetes therapy. Treatment was uptitrated to achieve target fasting plasma glucose <126 mg/dl; CHF medications were adjusted as appropriate. RESULTS The LVEF was similar in both groups at baseline (RSG 35.3 +/- 6.2%, PLB 35.7 +/- 7.8%) and after 52 weeks of treatment (mean difference 1.49%, p = 0.1). Glycemic control was significantly better in the RSG group (mean difference in hemoglobin A1c -0.65%, p < 0.0001). There were significantly more adjudicated events in the RSG group of new or worsening edema (RSG n = 28 [25.5%]; PLB n = 10 [8.8%]; p = 0.005) and increased CHF medication (RSG n = 36 [32.7%], PLB n = 20 [17.5%]; p = 0.037), but no significant difference between groups for other adjudicated end points. A similar proportion of patients withdrew from each treatment group because of adverse events. CONCLUSIONS After 52 weeks of treatment, RSG improved glycemic control but did not adversely affect LVEF in patients with T2DM and NYHA functional class I to II CHF. More fluid-related events occurred with RSG, although these generally did not lead to withdrawal from the study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2006.10.077

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 20

  1. Bell, 2003, Heart failure: the frequent, forgotten, and often fatal complication of diabetes, Diabetes Care, 26, 2433, 10.2337/diacare.26.8.2433 · DOI · Paper page
  2. Factor, 1980, Clinical and morphological features of human hypertensive-diabetic cardiomyopathy, Am Heart J, 99, 446, 10.1016/0002-8703(80)90379-8 · DOI · Paper page
  3. Taegtmeyer, 2002, Adaptation and maladaptation of the heart in diabetes: part I: general concepts, Circulation, 105, 1727, 10.1161/01.CIR.0000012466.50373.E8 · DOI · Paper page
  4. Diamant, 2003, Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence, Drugs, 63, 1373, 10.2165/00003495-200363130-00004 · DOI · Paper page
  5. Ghazzi, 1997, Cardiac and glycemic benefits of troglitazone treatment in NIDDM, Diabetes, 46, 433, 10.2337/diab.46.3.433 · DOI · Paper page
  6. Nesto, 2003, Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association, Circulation, 108, 2941, 10.1161/01.CIR.0000103683.99399.7E · DOI · Paper page
  7. Cheng, 2004, Thiazolidinedione-induced congestive heart failure, Ann Pharmacother, 38, 817, 10.1345/aph.1D400 · DOI
  8. Delea, 2003, Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study, Diabetes Care, 26, 2983, 10.2337/diacare.26.11.2983 · DOI · Paper page
  9. Kermani, 2003, Thiazolidinedione-associated congestive heart failure and pulmonary edema, Mayo Clin Proc, 78, 1088, 10.4065/78.9.1088 · DOI
  10. Singh, 2004, Rosiglitazone and heart failure: long-term vigilance, J Cardiovasc Pharmacol Ther, 9, 21, 10.1177/107424840400900i104 · doi:10.1177/107424840400900i104
  11. Srivastava, 2004, Thiazolidinediones and congestive heart failure—exacerbation or new onset of left ventricular dysfunction?, Diabet Med, 21, 945, 10.1111/j.1464-5491.2004.01274.x · DOI
  12. Schiller, 1989, Recommendations for quantitation of the left ventricle by two-dimensional echocardiography, J Am Soc Echocardiogr, 2, 358, 10.1016/S0894-7317(89)80014-8 · DOI · Paper page
  13. St. John Sutton, 2002, A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes, Diabetes Care, 25, 2058, 10.2337/diacare.25.11.2058 · DOI · Paper page
  14. Doughty, 2004, Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy, Circulation, 109, 201, 10.1161/01.CIR.0000108928.25690.94 · DOI · Paper page
  15. Young, 1998, Superiority of ‘triple’ drug therapy in heart failure: insights from the PROVED and RADIANCE trials, J Am Coll Cardiol, 32, 686, 10.1016/S0735-1097(98)00302-7 · DOI
  16. Wang, 2004, Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome, Am J Cardiol, 93, 362, 10.1016/j.amjcard.2003.10.022 · DOI
  17. Pitale, 2000, Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM), Diabetes Care, 23, 1316, 10.2337/diacare.23.9.1316 · DOI
  18. Kubo, 2004, Development and validation of a patient questionnaire to determine New York Heart Association classification, J Card Fail, 10, 228, 10.1016/j.cardfail.2003.10.005 · DOI
  19. Piccini, 2004, New insights into diastolic heart failure: role of diabetes mellitus, Am J Med, 116, 64S, 10.1016/j.amjmed.2003.10.021 · DOI
  20. Dormandy, 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial, Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9 · DOI · Paper page

Cited by

Metadata

Authors
Dargie, H. J., Hildebrandt, P. R., Riegger, G. A. J., McMurray, J. J. V., McMorn, S. O., Roberts, J. N., Zambanini, A., & Wilding, J. P. H.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2007-04
Volume
49
Issue
16
Pages
1696-1704
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2005888288
Cited by
206
References
1
FWCI
18.55
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.